1) Diagnosis of acute ischemic stroke and 2) evidence-based medicine (Part 3). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Peter Schellinger about his paper on diagnosis of acute ischemic stroke. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about digiti quinti sign. In the next part of the podcast Dr. Michael Benatar interviews Dr. Mark Conaway for part three on evidence-based medicine probability, odds, and odds ratio for our Lesson of the Week. The participants had nothing to disclose except Drs. Kissela, Schellinger and Fugate. Dr. Kissela served on the scientific advisory board for Allergan, Inc in 2009; served as a consultant for Allergan for 2-day meeting in 2009; received honoraria from CME program and unrestricted educational grants; received research support from the NIH [R01 NS 30678], [N01 NS 081588], [1Ul1 RR026314] and received compensation for reviewing records for several medical/legal cases regarding stroke.Dr. Schellinger has served/serves on scientific advisory boards for Boehringer Ingelheim, ImaRx Therapeutics, Photothera, Cerevast, and CoAxia, Inc.; has served/serves on speakers' bureaus for and received funding for travel and speaker honoraria from Boehringer Ingelheim, Sanofi, ImaRx Therapeutics, Photothera, Cerevast, CoAxia, Inc., Solvay Pharmaceuticals, Inc., and GlaxoSmithKline; serves on editorial boards of Stroke and European Neurology; receives royalties from the publication of NeuroIntensiv (Springer, 2008) and received royalties from the publication of Stroke MRI (Steinkopff, 2004); has served as a consultant for CoAxia, Inc., Photothera, Cerevast, ImaRx, and Boehringer Ingelheim; and has provided expert testimony, affidavits, and acted as a witness or consultant in legal proceedings.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section.